PACB - pacb.com Debt to Book Capitalization Ratio
Management at Pacific Biosciences (PACB), which develops DNA-based products, is currently radically optimizing expenses to restore shareholder confidence. The development of analytics and the fight against diseases rely on synergy with Google Health and scientific centers, with the indicator standing at 0.00. This chart of the market trend in monetary terms confirms the company's significant pricing power due to the exclusive accuracy of Revio systems in sequencing.
Metric breakdowns and analytics for Pacific Biosciences of California, Inc. (PACB)
Assessing leverage through the total liabilities-to-equity ratio allows for the determination of the financial stability of Pacific Biosciences (PACB) and the risk of over-borrowing. By analyzing the proportion of liabilities within the balance sheet capitalization, an investor can see how effectively the funds allocated to the development of DNA sequencing in partnership with Google Health are balanced between equity and debt to optimize return on assets.